Deals

Des recherches montrent que l’asthme et le diabète de type 2 (DT2) sont liés au-delà du hasard, partageant des facteurs inflammatoires et métaboliques. Cette association souligne l’importance d’une surveillance accrue et d’une prise en charge adaptée pour prévenir les complications chez les patients

Avista VC acquires OTC CMO Trillium; FDA deputy commissioner Jones to open CRN conference; AG1 founder steps down, COO moves up to CEO; ChromaDex hires general counsel; Ajinomoto, Shiru partner to develop sweet proteins; and change at ingredient provider LBB helm.

Church & Dwight’s slower sales at retail in June-July than in January-May point to still slower results for rest of year. It doesn’t expect second-half help from gummy vitamin lines or give them a full vote of confidence for remaining in portfolio.

Unilever hopes to double the value of its product innovations this year, ultimately targeting as many as 12 innovations, each costing more than €100m, beginning in 2025, CEO Hein Schumacher says during 25 July earnings presentation.

Analysts tracking consumer health product firms in the US anticipatevApril-June results lower than a year ago across most businesses. While some results will be lower on comparisons with strong growth in 2023, others will reflect a slow allergy season, retailers’ inventories remaining high as consumer spending slows or firms continuing to recover from supply chain problems.

CV Sciences closes purchase of Elevated Softgels, a manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. Captek Softgel starts gummy supplement production at a 60,000-square foot facility.

Along with latest results, Kenvue says as its “transitions services agreement” with J&J ends, its board approves reducing global workforce by around 4%. It expects around $275m in pre-tax restructuring costs in both 2024 and 2025 without changes to its capital allocation priorities.

Canadian firm’s eye health supplements Occuvite and PreserVision remain top sellers, with ReNu and Biotrue contact lens solutions and Lumify eye drops and skin care line rounding out its top 10 revenue generators.

Attacks on shipping since November in the Red Sea lead shipping lines to re-route vessels south of Africa, spiking shipping costs. Perrigo began 2024 saying it expects sales of Opill oral contraceptive to start early in the first quarter, but now expects to start late in the quarter.

21 Invest has taken a majority stake it Italian food supplements player Omega Pharma Srl.

An unexpected merger between Korea's Hanmi Pharm Group and chemical group OCI may raise eyebrows in terms of likely synergies, but analysts are viewing the planned transaction positively in terms of future cash flow. However, resistance from some members of Hanmi's founder family may mean a possible leadership struggle at the pharma company.

Yellow Wood Partners LLC, a Boston-based private equity company that purchased Suave in North America from Unilever PLC early this year, has signed a binding offer to acquire 20 more personal care brands from the UK firm with its planned acquisition of Elida Beauty.

Consumer health space’s “unique dynamics that slightly differ from the traditional CPG world,” says Kenvue CEO Thibaut Mongon, “is that you can expand usage occasions almost indefinitely.”

CEO Thibaut Mongon says Kenvue’s priorities since separation from J&J include “maybe something that was not obvious in the previous world,” when employees “could not relate to how” their work mattered. North America president change comes with skin health and beauty portfolio “not where we want to be.”

"Otsuka is very, very committed to nutraceuticals generally, and supplements specifically,” says Pharmavite CEO Jeff Boutelle.

“This acquisition, plus our existing women's health brands of Equelle and Uqora, positions us, the combined group, as the leader in women's health in nutraceuticals in the US,” says Pharmavite CEO Jeff Boutelle. Bonafide markets supplements for long-term, sustainable support for needs that compound with age, including hot flashes, vaginal dryness, vaginal microbiome and sexual satisfaction.

HedoniaUSA appoints Dany Sfeir CEO; FinaFlex collaborates with bodybuilding champion Branch Warren; Relaxium supplements recruits NFL Hall of Famer Dan Marino; Arizona Nutritional Supplements founders Aaron Blunck and Jonathan Pinkus re-acquire business.

Recently spun out, NoviaHealth will have exclusive right to commercialize future Synbiotic Health discoveries, including new strains and other intellectual property.

More brands, particularly those acquired prior to Unilever’s 2019 shift in M&A strategy, could be on the chopping block, according to CEO Hein Schumacher, who took the helm in July. His targeted action plan includes investments to accelerate innovation and increase brand and marketing support.

Kenvue also not standing apart from competitors concerning headwinds from foreign exchange rates, a slow start to the cough/cold season and looking ahead to FDA decision on oral phenylephrine, it reports with its third-quarter results.